Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Non-randomized, First-in-human, Multi-centre Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Locally Administered DT01 in Combination With Radiotherapy and Concomitant Dose of Chloroquine in Patients With Local Metastatic Melanoma With Relapsed Cutaneous/Subcutaneous Tumors Including Melanoma-in-transit

NCT01469455 is registered in ClinicalTrials.gov with DNA Therapeutics as lead sponsor.

NCT NCT01469455
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01469455 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Non-randomized, First-in-human, Multi-centre Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Locally Administered DT01 in Combination With Radiotherapy and Concomitant Dose of Chloroquine in Patients With Local Metastatic Melanoma With Relapsed Cutaneous/Subcutaneous Tumors Including Melanoma-in-transit
Lead sponsor
DNA Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2011
Completion date
July 31, 2015
Enrollment
27 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

local metastatic melanoma